Welcome to our dedicated page for Cameco SEC filings (Ticker: CCJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Cameco Corporation (CCJ) SEC filings, where the company furnishes its U.S. regulatory disclosures as a foreign private issuer. Cameco files an annual report on Form 40-F, which includes its audited annual financial statements prepared in accordance with IFRS, management’s discussion and analysis (MD&A), and its Canadian annual information form. These documents outline segment performance for Uranium, Fuel Services and Westinghouse, along with risk factors and other corporate information.
Between annual reports, Cameco submits Form 6-K current reports to furnish press releases, quarterly MD&A, condensed consolidated interim unaudited financial statements and officer certifications under the Sarbanes-Oxley Act. Recent 6-K filings listed in the input include exhibits such as quarterly financial statements, MD&A for periods ended June 30 and September 30, 2025, press releases on operational updates, long-term contracts and strategic partnerships, and certifications from the chief executive officer and chief financial officer.
For investors analyzing Cameco’s uranium and nuclear fuel business, the 40-F and 6-K filings are primary sources for details on segment results, production volumes, long-term contracting, non-IFRS measures like adjusted net earnings and adjusted EBITDA, and disclosures about joint ventures such as JV Inkai. The filings also document Cameco’s equity-accounted investment in Westinghouse Electric Company, including its share of Westinghouse’s adjusted EBITDA and net earnings or losses, and information about projects in which Westinghouse participates.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify changes in production outlook, contract commitments, or segment performance without reading every page. Users can review annual Form 40-F reports, interim 6-Ks, and related exhibits, and then rely on AI-generated overviews to understand how Cameco describes its financial condition, operational plans and exposure across the nuclear fuel cycle.
Cameco Corporation (CCJ) filed a Form 144 disclosing a proposed sale of 19,460 common shares with an aggregate market value of $1,680,000. The filing shows the shares represent part of the issuer's outstanding common stock of 435,387,448 shares and names the intended sale date as 09/15/2025 on the NYSE. The shares were acquired on 09/15/2025 through a stock option exercise from Cameco Corporation and payment was in cash. The filer reports no securities sold during the past three months and includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Cameco Corporation (CCJ) notice: an individual intends to sell 500 common shares on the NYSE through Solium Financial on 09/10/2025 for an aggregate market value of $39,735. The shares were acquired from long‑term incentive vesting in 2018–2019 (129, 184, and 187 shares on specific vesting dates) with cash payment at acquisition. The filer reports no securities sold in the past three months and affirms they are not aware of any undisclosed material adverse information about the issuer. This form is a Rule 144 notice of proposed sale and documents the planned transaction and acquisition history.
Cameco Corporation (CCJ) submitted a Form 144 reporting a proposed sale of 500 common shares with an aggregate market value of 36,170.00, to be sold approximately on 06/24/2025 on the NYSE through BMO Investorline.
The filing shows those shares were acquired by open-market purchases on 11/04/2014 (400 shares) and 11/06/2014 (100 shares), paid in cash. It lists total shares outstanding of 435,387,448 and records a sale of 500 shares on 06/23/2025 with gross proceeds of 34,860.00. The seller certifies they are unaware of any undisclosed material adverse information.
Cameco Corporation (CCJ) filed a Form 144 notifying a proposed sale of 500 common shares. The filing lists the broker as BMO Investorline (100 King St W, Toronto) and shows an aggregate market value of $34,860 for the shares to be sold on the NYSE with an approximate sale date of 06/23/2025. The company’s shares outstanding are reported as 435,387,448.
The securities were acquired on 11/04/2014 in an open-market purchase with payment in cash. The filing reports "Nothing to Report" for securities sold during the past three months. The supplied content does not include the filer CIK or the name of the person for whose account the securities are to be sold.
Cameco Corporation filed a Form 6-K with the SEC on June 28, 2025, reporting as a foreign private issuer. The filing primarily serves as a cover document indicating that the company has issued a press release dated June 26, 2025.
Key filing details:
- The company confirms it files annual reports using Form 40-F rather than Form 20-F
- Document is signed by Sean A. Quinn, Senior Vice-President, Chief Legal Officer and Corporate Secretary
- Principal executive offices are located in Saskatoon, Saskatchewan, Canada
- Filing complies with Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
Note: The actual content of the press release mentioned in the exhibit is not included in this filing document, making it impossible to analyze the specific announcement or its potential market impact.
On 27 May 2025, a Form 144 was filed for Cameco Corporation (symbol CCJ) signaling the intent to sell 3,252 common shares through CIBC Investor Services on the Toronto Stock Exchange. The proposed transaction carries an aggregate market value of C$196,648 and equates to roughly 0.0007 % of Cameco’s 435,316,918 shares outstanding, indicating a negligible impact on the company’s overall float. The shares were originally acquired on 11 Feb 2020 via open-market purchases for cash. No additional insider sales have been reported during the preceding three-month period.
The filing does not reveal the seller’s identity or their relationship to Cameco, but under Rule 144 the filer certifies that no undisclosed material adverse information exists. Because the share count is small and represents an immaterial fraction of total shares, the filing is unlikely to influence liquidity, control, or valuation. Nevertheless, investors often track Form 144 notices for early insight into potential insider sentiment or future trading activity.